TrovaGene Inc (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer Monitoring℠ platform will be presented at the 16th World Conference on Lung Cancer in Denver, Colorado. Hatim Husain, M.D., University of California, San Diego School of Medicine will present the results in Oral Session 38: Liquid Biopsies. The data highlight the ability to monitor real time response to targeted therapy.

“We have been able to model some of the early effects of chemotherapeutic agents on patients to model tumor lysis,” stated Dr. Husain. “In this expanded data set, we were able to closely monitor the dynamic changes in urinary EGFRmutation load at initial therapy, recurrence, and in retreatment scenarios.” (Original Source)

Shares of TrovaGene Inc closed yesterday at $6.15. TROV has a 1-year high of $13.58 and a 1-year low of $4. The stock’s 50-day moving average is $6.80 and its 200-day moving average is $8.38.

On the ratings front, TrovaGene has been the subject of a number of recent research reports. In a report issued on August 14, Leerink Swann analyst Dan Leonard initiated coverage with a Buy rating on TROV and a price target of $9, which implies an upside of 46.3% from current levels. Separately, on July 8, Maxim Group’s Jason Kolbert reiterated a Buy rating on the stock and has a price target of $13.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Dan Leonard and Jason Kolbert have a total average return of 6.9% and -10.0% respectively. Leonard has a success rate of 50.0% and is ranked #1100 out of 3752 analysts, while Kolbert has a success rate of 31.8% and is ranked #3735.

TrovaGene Inc is a development stage molecular diagnostic company. It focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring.